Abstract 111P
Background
In present time, neoadjuvant chemoradiotherapy for distal rectal cancer is part of clinical guidelines in Europe and the USA. According to the literature, there are no unified standards for upper rectal cancer.
Methods
The study included data from patients over 18 years old, with histologically proven adenocarcinoma with TNM stage T2-4aN0-2M0 and tumour location in the upper part of the rectum (10-15 sm). In the main group (A), preoperative chemoradiotherapy was performed: short-course radiotherapy (5x5 Gy), with capecitabine 2000 mg/m2 × 2 times for 14 days, followed by surgical treatment. In the control group (B) only surgical treatment was performed - partial or total mesorectumectomy.
Results
From January 2004 to December 2014, 226 (99.6%) underwent surgical treatment. The incidence of postoperative complications byClavien-Dindo scale was:group A - 17 (16.5%) and group B - 11 (8.9%). Local recurrences in group A occurred in 1 patient (1.2%), in group B - in 3 (2.5%) patients (p = 0.413). Distant metastases in group A developed in 10 (10.2%) patients, in group B -15 (12.6%) patients (p = 0.581). Overall survival was in group A - 90.6%, recurrence-free - 89.6%; in group B - 82.8% and 81.9%, respectively (p = 0.46). Multivariate analysis showed that the affected regional lymph nodes were the main predictor of poor prognosis (p = 0.001, OR = 0.094, CI = 0.035-0.250) and significantly reduced the 5-year disease-free survival rate (p = 0.001, OR = 4.213, CI = 2.010-8.830).
Conclusions
The results of the study showed that neoadjuvant chemoradiotherapy in comparison with the surgical method does not have an advantage for patients with upper rectum cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Jasur Madyarov.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
175P - Hypermethylation of the PCDHB15 promoter predicts the prognosis in gastric cancer
Presenter: Yu-ting Lee
Session: Poster display session
Resources:
Abstract
176P - DCLK1 promotes tumour invasion and metastasis through epithelial-mesenchymal transition and the MEK/ERK pathway in esophageal squamous cell carcinoma
Presenter: Jiannan Yao
Session: Poster display session
Resources:
Abstract
177P - Comparison of nab-paclitaxel plus ramcirumab and paclitaxel plus ramcirumab in patients with pretreated metastatic gastric cancer
Presenter: Yosuke Horita
Session: Poster display session
Resources:
Abstract
178P - Chief cell in stomach have stem cell activity and potential to develop gastric cancer
Presenter: Akihiro Yamamura
Session: Poster display session
Resources:
Abstract
179P - Postoperative Adjuvant transarterial chemoembolization versus surgery alone for resected hepatocellular carcinoma: A propensity-score matching study
Presenter: Mingyu Chen
Session: Poster display session
Resources:
Abstract
180P - LHPP inhibit the cell proliferation and EMT via the TGFβ/SMAD3 signaling pathway in iCCA
Presenter: Dan Wang
Session: Poster display session
Resources:
Abstract
181P - The emerging role of third-line gemcitabine plus nab-paclitaxel in advanced pancreatic adenocarcinoma
Presenter: Andrew Dean
Session: Poster display session
Resources:
Abstract
182P - Durable response to second-line m-FOLFIRINOX for advanced pancreatic adenocarcinoma in patients with performance status of two or less
Presenter: Adarsh Das
Session: Poster display session
Resources:
Abstract
183P - Epidemiologic profile of gastric cancer in East Azerbaijan, Iran: 2 years population-based cancer registry results
Presenter: Pooneh Jabbaripour
Session: Poster display session
Resources:
Abstract
184P - Expression pattern of CDK12 protein in gastric cancer and its positive correlation with CD8+ cell density and CCL12 expression
Presenter: Jun Ji
Session: Poster display session
Resources:
Abstract